Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

NCT03768414 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT03768414
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03768414 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 3
Overall status
Completed
Start date
February 7, 2019
Completion date
October 28, 2024
Enrollment
452 (actual)
Sites
692

Conditions

As the registry lists them; a condition with its own page is linked.

stage iii distal bile duct cancer ajcc v8, stage iii gallbladder cancer ajcc v8, stage iii intrahepatic cholangiocarcinoma ajcc v8, stage iiia distal bile duct cancer ajcc v8, stage iiia gallbladder cancer ajcc v8, stage iiia intrahepatic cholangiocarcinoma ajcc v8, stage iiib distal bile duct cancer ajcc v8, stage iiib gallbladder cancer ajcc v8, stage iiib intrahepatic cholangiocarcinoma ajcc v8, stage iv distal bile duct cancer ajcc v8, stage iv gallbladder cancer ajcc v8, stage iv intrahepatic cholangiocarcinoma ajcc v8, stage iva gallbladder cancer ajcc v8, stage ivb gallbladder cancer ajcc v8, unresectable extrahepatic bile duct carcinoma, unresectable gallbladder carcinoma, unresectable intrahepatic cholangiocarcinoma